KR-20260065703-A - COMPOSITION FOR INHIBITING SKIN PIGMENTATION

Abstract

The present invention relates to a composition for inhibiting skin pigmentation, comprising a peptide represented by SEQ ID NO. 1 as an active ingredient.

Inventors

• 박태준
• 강희영
• 이영삼
• 김진철
• 김영은
• 김상현

Assignees

• 아주대학교산학협력단
• 재단법인대구경북과학기술원

Dates

Publication Date

20260511

Application Date

20241101

Claims (14)

1. Comprising a peptide represented by SEQ ID NO. 1 as an active ingredient, Composition for inhibiting skin pigmentation.
2. In Article 1, The above peptide is synthesized from the amino acid sequence of the CXCR4 activation motif portion of SDF1 (Stromal cell-derived factor-1), Composition for inhibiting skin pigmentation.
3. In Article 1, The activity of the cAMP/PKA/CREB pathway is reduced by the above peptide, Composition for inhibiting skin pigmentation.
4. In Article 1, The expression of MITF mRNA is reduced by the above peptide, Composition for inhibiting skin pigmentation.
5. In Article 1, The expression of TYR mRNA is reduced by the above peptide, Composition for inhibiting skin pigmentation.
6. In Article 1, The reduction of tyrosinase activity by the above peptide, Composition for inhibiting skin pigmentation.
7. In Article 1, The above skin pigment contains melanin, Composition for inhibiting skin pigmentation.
8. Comprising a peptide represented by SEQ ID NO. 1 as an active ingredient, Pharmaceutical composition for the prevention or treatment of skin pigmentation disorders.
9. In Article 8, The above skin pigmentation disorders include those selected from the group consisting of melasma, freckles, lentigo, nevi, drug-induced pigmentation, post-inflammatory pigmentation, and hyperpigmentation occurring in dermatitis. Pharmaceutical composition for the prevention or treatment of skin pigmentation disorders.
10. In Article 8, The above pharmaceutical composition for the prevention or treatment of skin pigmentation disorders further comprises a pharmaceutically acceptable carrier. Pharmaceutical composition for the prevention or treatment of skin pigmentation disorders.
11. In Article 10, The above carrier comprises a material selected from the group consisting of lactose, dextrose, sucrose, sorbitol, mannitol, starch, acacia gum, calcium phosphate, alginate, gelatin, calcium silicate, microcrystalline cellulose, polyvinylpyrrolidone, cellulose, water, syrup, methyl cellulose, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate, menthol, mineral oil, and combinations thereof. Pharmaceutical composition for the prevention or treatment of skin pigmentation disorders.
12. In Article 8, The above pharmaceutical composition for the prevention or treatment of skin pigmentation disorders further comprises a component selected from the group consisting of preservatives, solubilizers, stabilizers, humectants, sweeteners, colorants, flavorings, salts, buffers, antioxidants, lubricants, emulsifiers, suspending agents, preservatives, and combinations thereof. Pharmaceutical composition for the prevention or treatment of skin pigmentation disorders.
13. Comprising a peptide represented by SEQ ID NO. 1 as an active ingredient, Cosmetic composition for skin whitening.
14. Comprising a peptide represented by SEQ ID NO. 1 as an active ingredient, Health functional food composition for skin whitening.

Description

Composition for Inhibiting Skin Pigmentation The present invention relates to a composition for inhibiting skin pigmentation. Epidermal melanocytes are cells that synthesize melanin pigment. Melanin plays an important role as a natural sunscreen that absorbs ultraviolet (UV) radiation. However, excessive production of melanin causes hyperpigmentation, which manifests as melasma or solar lentigo. Skin pigmentation is a complex process regulated by interactions among adjacent skin cells, such as melanocytes, keratinocytes, fibroblasts, and inflammatory cells. Recent studies have revealed that dermal components, particularly soluble factors such as Dickkopf-related protein-1 (DKK1) and neuregulin-1 secreted by dermal fibroblasts, play an important role in determining human skin color. Meanwhile, the inventor of the present invention, Korean Registered Patent No. 10-1883142, presented the possibility of developing a skin whitening substance using SDF1 (Stromal cell-derived factor-1) as an active ingredient. However, SDF1 had several limitations in application to cosmetic formulations due to its size. Therefore, there is a need to develop a composition suitable for cosmetic use that has an inhibitory effect on skin pigmentation while also possessing a relatively small size. Figure 1 is a schematic diagram showing the origin of a CXCR4-specific SDF-1 peptide according to the present invention. Figure 2 is the result of the cytotoxicity evaluation of SDF-1 peptide on melanocytes according to one experimental example of the present invention. Figure 3 is the result of evaluating the effect of SDF-1 peptide on melanin-producing gene expression according to one experimental example of the present invention. Figure 4 is the result of evaluating the tyrosinase activity and melanin production inhibitory effect of SDF-1 peptide according to one experimental example of the present invention. Figure 5 is the result of evaluating the effect of SDF-1 peptide on the cAMP/CREB signaling pathway according to one experimental example of the present invention. Embodiments of the present invention are described below with reference to the attached drawings to enable those skilled in the art to easily implement the invention. However, the present invention may be embodied in various different forms and is not limited to the embodiments described herein. Furthermore, in order to clearly explain the present invention in the drawings, parts unrelated to the explanation have been omitted, and similar parts throughout the specification are denoted by similar reference numerals. Throughout this specification, when a part is described as being "connected" to another part, this includes not only cases where they are "directly connected," but also cases where they are "electrically connected" with other elements interposed between them. Throughout the entire specification, when a component is described as being located "on," "on top," "on top," "under," "on bottom," or "on bottom" of another component, this includes not only cases where the component is in contact with the other component but also cases where another component exists between the two components. Throughout this specification, when a part is described as "comprising" a certain component, this means that, unless specifically stated otherwise, it does not exclude other components but may include additional components. As used herein, terms of degree such as “about,” “substantially,” etc., are used to mean at or near the stated value when inherent manufacturing and material tolerances are presented in the stated meaning, and are used to prevent unscrupulous infringers from unfairly exploiting the disclosure in which precise or absolute values are mentioned to aid in understanding the invention. Furthermore, throughout this specification, “a step of” or “a step of” does not mean “a step for”. Throughout this specification, the term “combination thereof” included in the Markush-type expression means one or more mixtures or combinations selected from the group consisting of the components described in the Markush-type expression, and means including one or more selected from the group consisting of said components. Throughout the entire specification, the description "A and/or B" means "A, B, or A and B". Hereinafter, the composition for inhibiting skin pigmentation of the present invention will be described in detail with reference to the embodiments, examples, and drawings. However, the present invention is not limited to these embodiments, examples, and drawings. As a technical means to achieve the above-mentioned technical problem, the first aspect of the present invention provides a composition for inhibiting skin pigmentation comprising a peptide represented by SEQ ID NO. 1 as an active ingredient. The composition for inhibiting skin pigmentation according to the present invention can effectively inhibit melanin production by reducing the activity of the cAMP/PKA/CREB pathway